[Endoscopic polypectomy of colorectal adenomas: Monitoring patients in order to review the colonoscopic surveillance interval]. / Polipectomía endoscópica de adenomas colorrectales: Seguimiento de los pacientes con el objeto de evaluar el intervalo entre las videocolonoscopías de control.

OBJECTIVE: To determine the risk of advanced adenomas at surveillance colonoscopy after polipectomy. To review the colonoscopic surveillance interval and to compare the prevalence of adenomas in patients with low-risk and high-risk adenomas at screening colonoscopies. METHODS: A cohort retrospective study. It was used a database of colonoscopies performed between 1999 and 2012. Seven hundred and sixty patients who had adenomas at first colonoscopy were included (465 males and 295 females, mean age 62 years old). They were divided into two groups: group A, low-risk adenomas, and group B, high-risk adenomas. In each group, it was compared the presence of adenomas in videocolonoscopies performed at 3 and 5 years. RESULTS: At the first colonoscopy 409 patients (53.8%) belonged to group A and 351 (46.2%) than group B. In both groups the risk of new advanced adenomas in endoscopic surveillance at 5years was similar to the control at 3 years. Comparing both groups, the risk of new advanced adenomas in endoscopic surveillance at 3 years in group B was 1.96 times greater than in group A (P = 0.012). CONCLUSIONS: At present, surveillance endoscopy is performed before the suggested interval. In both groups there were no statistically significant differences between surveillance control at 3 or 5 years. However, 62% of patients in group B have developed new advanced adenomas in endoscopic surveillance at 3 years. Therefore, it is recommended the endoscopic control with this interval.

Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study.

METHODS: A multicenter cross-sectional study involving seven referral centers from three cities of Argentina was undertaken. Patients with a diagnosis of ulcerative colitis (UC), Crohn's disease (CD), or indeterminate colitis (IBDU/IC) were invited to answer an anonymous survey, which included a 5-point Likert scale to evaluate adherence to therapies. Independent variables associated with inadequate adherence were evaluated. RESULTS: Overall, 447 UC/IBDU and 135 CD patients were enrolled. Median age was 37 years (range 21-72); 39.8% were male; median time from diagnosis was 6 years (0.5-35). 91.4% were under treatment with at least one oral medication; 50.3% of patients reported inadequate adherence to oral medications. Patients with UC/IBDU had a lower risk of inadequate adherence when compared to patients with CD (OR 0.57 (0.37-0.87)). 21.8% reported inadequate adherence to biologics; subcutaneous administration was significantly associated with inadequate adherence to biologics (OR 4.8 (1.57-14.66)). CONCLUSION: Inadequate treatment adherence is common among patients with IBD, and potentially modifiable factors were identified.